Compare IMPP & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMPP | PROF |
|---|---|---|
| Founded | 1981 | N/A |
| Country | Greece | Canada |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 234.7M | 263.8M |
| IPO Year | 2021 | 2017 |
| Metric | IMPP | PROF |
|---|---|---|
| Price | $5.31 | $6.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 358.1K | 103.0K |
| Earning Date | 05-22-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,098,000.00 |
| Revenue This Year | $51.79 | $92.40 |
| Revenue Next Year | $6.97 | $64.10 |
| P/E Ratio | $3.68 | ★ N/A |
| Revenue Growth | N/A | ★ 50.73 |
| 52 Week Low | $3.15 | $3.92 |
| 52 Week High | $6.57 | $8.95 |
| Indicator | IMPP | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 59.91 | 46.50 |
| Support Level | $4.64 | $6.47 |
| Resistance Level | $5.30 | $7.04 |
| Average True Range (ATR) | 0.22 | 0.32 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 76.67 | 37.78 |
Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil, and jet fuel, as well as edible oils and chemicals.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.